Greg Slabodkin
Editor-in-Chief at Pharma Manufacturing
News Editor at #BioSpace #biopharma, #pharma, #biotechnology, #bigpharma, #pharmaceuticals
Articles
-
2 days ago |
pharmamanufacturing.com | Greg Slabodkin
German pharmaceutical and agricultural company Bayer said the potential impact of tariffs is manageable and it doesn’t see a need to adjust its manufacturing footprint in Europe and the United States.
-
6 days ago |
pharmamanufacturing.com | Greg Slabodkin
Japanese drugmaker Takeda plans to invest $30 billion in its U.S. operations over the next five years, according to CEO Christophe Weber, who made the announcement Thursday during the company’s earnings call. “This reflects the fact that the U.S. is the world’s leading market for biopharmaceutical innovation,” Weber said, while emphasizing that the investment strategy is “not new” and is to maintain Takeda’s presence in the U.S. which includes a “massive” manufacturing network.
-
1 week ago |
pharmamanufacturing.com | Greg Slabodkin
As the demand for complex active pharmaceutical ingredients (APIs) continues to grow, Germany-based contract development and manufacturing organization Axplora is investing in the infrastructure to meet the needs of customers in antibody-drug conjugates (ADCs) and GLP-1 receptor agonists (GLP-1s) — two of the biopharma industry’s hottest areas.
-
1 week ago |
pharmamanufacturing.com | Greg Slabodkin
Eli Lilly CEO Dave Ricks is the latest head of a major drugmaker to urge President Trump to drop tariffs and embrace tax policy to bring pharmaceutical manufacturing back to the United States. While Lilly supports the Trump administration’s goal of increasing investment in domestic manufacturing, Ricks told analysts during a Thursday earnings call that the company doesn’t believe tariffs are the “right mechanism” for achieving that objective.
-
1 week ago |
pharmamanufacturing.com | Greg Slabodkin
In a move to optimize its cell therapy manufacturing network, Bristol Myers Squibb is ending operations at its viral vector production facility in Libertyville, Illinois. The company will shift the work to a BMS site in Devens, Massachusetts. “This is a strategic move toward a more cost effective, scalable, and integrated end-to-end manufacturing model that will serve patients for years to come,” a BMS spokesperson said in an emailed statement.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 2K
- Tweets
- 9K
- DMs Open
- No
#Roche says #Trump's #MostFavoredNation #executiveorder jeopardizes its $50 billion U.S. investment. If it goes into effect, Roche's "ability to fund the significant investments previously announced in the U.S. will be in question." https://t.co/k6VOeuuoSB #pharmamanufacturing
#Recipharm and #ProductLifeGroup team to help #pharmaceutical companies speed up development timelines and improve #regulatory outcomes, with Recipharm's #manufacturing and development capabilities and PLG's regulatory and market access expertise. https://t.co/dTNPV87FEz #CDMO
#WuXiBiologics sells drug product (DP) plant in $168 million deal with #TerumoCorporation. The sale of WuXi's facility in Germany is meant to enable the Chinese #CRDMO to focus on building DP #manufacturing in Singapore. https://t.co/Rz0sCrF1Cn #CDMO #contractmanufacturing #China